Drugs / Molgramostim
Molgramostim
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02468908 | May → Oct 2015 | acute respiratory distress syndrome, bronchiectasis, cystic fibrosis, pulmonary alveolar proteinosis | Savara Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05501340 | Sep → Dec 2022 | peritoneal neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 27 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04823962 | Mar 2021 → Dec 2023 | ulcer of lower limbs | Reponex Pharmaceuticals A/S | Unknown | No outcome recorded |
| Phase 2 | NCT04569877 | Sep 2020 → Jun 2022 | pneumonia, severe acute respiratory syndrome | University of Giessen | Completed | No outcome recorded |
| Phase 2 | NCT03597347 | Jun 2019 → Oct 2020 | cystic fibrosis, pulmonary non-tuberculous mycobacterial infection | Savara Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03421743 | Mar 2018 → Oct 2019 | pulmonary non-tuberculous mycobacterial infection | Savara Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03435900 | Feb → Jul 2018 | appendicitis | Herlev Hospital | Completed | Met primary |
| Phase 2 | NCT02595060 | Jun 2016 → Sep 2021 | acute respiratory distress syndrome | University of Giessen | Completed | No outcome recorded |
| Phase 2 | NCT02702180 | Mar 2016 → Apr 2019 | autoimmune pulmonary alveolar proteinosis | Savara Inc. | Completed | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01729663 | Apr 2009 → Dec 2018 | cutaneous melanoma | Laboratorio Pablo Cassará S.R.L. | Unknown | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06431776 | Oct 2025 → Jun 2027 expected | autoimmune pulmonary alveolar proteinosis | Savara Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04544293 | May 2021 → Nov 2023 overdue | autoimmune pulmonary alveolar proteinosis | Savara Inc. | Active not recruiting | Met primary |
| Phase 3 | NCT03482752 | Apr 2018 → Jan 2021 | autoimmune pulmonary alveolar proteinosis | Savara Inc. | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06546098 | — | autoimmune pulmonary alveolar proteinosis | Savara Inc. | Available | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 0 | NCT07341360 Background | Oct 2025 → Dec 2029 expected | pseudomyxoma peritonei | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT00925873 Comparator | Jun 1996 → Apr 2000 | acute myeloid leukemia | French Innovative Leukemia Organisation | Completed | No outcome recorded |
| Phase 4 | NCT00464217 Background | Oct 1998 → Dec 2008 | acute myeloid leukemia | PETHEMA Foundation | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Molgramostim | “Shorter Total Length of Stay After Intraperitoneal Fosfomycin, Metronidazole, and Molgramostim for Complicated Appendicitis” PMID 32432123 ↗ May 202015“The active substance: molgramostim (rhGM-CSF)” NCT04823962 ↗ “GM-CSF (molgramostim, Novartis)” NCT00925873 ↗ “Drug: Molgramostim” NCT05501340 ↗ |
| Known as | Leucomax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00464217 ↗ |
| Known as | rhGM-CSF | “This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with pneumonia associated acute respiratory distress syndrome (ARDS).” NCT02595060 ↗2“300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation” NCT02702180 ↗ “The active substance: molgramostim (rhGM-CSF)” NCT04823962 ↗ |
| Action | Activate | “Savara is studying an investigational drug called molgramostim nebulizer solution to see if it activates the cells that help clear surfactant from the lungs” NCT06546098 ↗ |
| Modality | Protein / enzyme biologic | “Inhaled molgramostim, a form of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF)” PMID 40973220 ↗ Sep 2025 |
| Route | Intravenous | “5 mcg/kg subcutaneous or endovenous” NCT00464217 ↗ |
| Route | Subcutaneous | “5 mcg/kg subcutaneous or endovenous” NCT00464217 ↗ |